Multimodal detection of molecular residual disease in high-risk locally advanced squamous cell carcinoma of the head and neck
© 2024. The Author(s)..
Up to 30% of patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) relapse. Molecular residual disease (MRD) detection using multiple assays after definitive therapy has not been reported. In this study, we included patients with LA-HNSCC (stage III Human Papilloma virus (HPV)-positive, III-IVB HPV-negative) treated with curative intent. Plasma was collected pre-treatment, at 4-6 weeks (FU1) and 8-12 weeks (FU2) post-treatment. Circulating tumor DNA (ctDNA) was analyzed using a tumor-informed (RaDaR®) and a tumor-naïve (CAPP-seq) assay. HPV DNA was measured using HPV-sequencing (HPV-seq) and digital PCR (dPCR). A total of 86 plasma samples from 32 patients were analyzed; all patients with at least 1 follow-up sample. Most patients were stage III HPV-positive (50%) and received chemoradiation (78%). No patients had radiological residual disease at FU2. With a median follow-up of 25 months, there were 7 clinical relapses. ctDNA at baseline was detected in 15/17 (88%) by RaDaR and was not associated with recurrence free survival (RFS). Two patients relapsed within a year after definitive therapy and showed MRD at FU2 using RaDaR; detection of ctDNA during follow-up was associated with shorter RFS (p < 0.001). ctDNA detection by CAPP-seq pre-treatment and during follow-up was not associated with RFS (p = 0.09). HPV DNA using HPV-seq or dPCR during follow-up was associated with shorter RFS (p < 0.001). Sensitivity and specificity for MRD at FU2 using RaDaR was 40% and 100% versus 20 and 90.5% using CAPP-seq. Sensitivity and specificity for MRD during follow-up using HPV-seq was 100% and 91.7% versus 50% and 100% using dPCR. In conclusion, HPV DNA and ctDNA can be detected in LA-HNSCC before definitive therapy. The RaDaR assay but not CAPP-seq may detect MRD in patients who relapse within 1 year. HPV-seq may be more sensitive than dPCR for MRD detection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Cell death and differentiation - 31(2024), 4 vom: 26. Apr., Seite 460-468 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sanz-Garcia, Enrique [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Circulating Tumor DNA |
|---|
| Anmerkungen: |
Date Completed 25.04.2024 Date Revised 27.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41418-024-01272-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368992365 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368992365 | ||
| 003 | DE-627 | ||
| 005 | 20240427232116.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41418-024-01272-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1390.xml |
| 035 | |a (DE-627)NLM368992365 | ||
| 035 | |a (NLM)38409276 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sanz-Garcia, Enrique |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Multimodal detection of molecular residual disease in high-risk locally advanced squamous cell carcinoma of the head and neck |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.04.2024 | ||
| 500 | |a Date Revised 27.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a Up to 30% of patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) relapse. Molecular residual disease (MRD) detection using multiple assays after definitive therapy has not been reported. In this study, we included patients with LA-HNSCC (stage III Human Papilloma virus (HPV)-positive, III-IVB HPV-negative) treated with curative intent. Plasma was collected pre-treatment, at 4-6 weeks (FU1) and 8-12 weeks (FU2) post-treatment. Circulating tumor DNA (ctDNA) was analyzed using a tumor-informed (RaDaR®) and a tumor-naïve (CAPP-seq) assay. HPV DNA was measured using HPV-sequencing (HPV-seq) and digital PCR (dPCR). A total of 86 plasma samples from 32 patients were analyzed; all patients with at least 1 follow-up sample. Most patients were stage III HPV-positive (50%) and received chemoradiation (78%). No patients had radiological residual disease at FU2. With a median follow-up of 25 months, there were 7 clinical relapses. ctDNA at baseline was detected in 15/17 (88%) by RaDaR and was not associated with recurrence free survival (RFS). Two patients relapsed within a year after definitive therapy and showed MRD at FU2 using RaDaR; detection of ctDNA during follow-up was associated with shorter RFS (p < 0.001). ctDNA detection by CAPP-seq pre-treatment and during follow-up was not associated with RFS (p = 0.09). HPV DNA using HPV-seq or dPCR during follow-up was associated with shorter RFS (p < 0.001). Sensitivity and specificity for MRD at FU2 using RaDaR was 40% and 100% versus 20 and 90.5% using CAPP-seq. Sensitivity and specificity for MRD during follow-up using HPV-seq was 100% and 91.7% versus 50% and 100% using dPCR. In conclusion, HPV DNA and ctDNA can be detected in LA-HNSCC before definitive therapy. The RaDaR assay but not CAPP-seq may detect MRD in patients who relapse within 1 year. HPV-seq may be more sensitive than dPCR for MRD detection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Circulating Tumor DNA |2 NLM | |
| 650 | 7 | |a DNA, Viral |2 NLM | |
| 700 | 1 | |a Zou, Jinfeng |e verfasserin |4 aut | |
| 700 | 1 | |a Avery, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Spreafico, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Waldron, John |e verfasserin |4 aut | |
| 700 | 1 | |a Goldstein, David |e verfasserin |4 aut | |
| 700 | 1 | |a Hansen, Aaron |e verfasserin |4 aut | |
| 700 | 1 | |a Cho, B C John |e verfasserin |4 aut | |
| 700 | 1 | |a de Almeida, John |e verfasserin |4 aut | |
| 700 | 1 | |a Hope, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Hosni, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Hahn, Ezra |e verfasserin |4 aut | |
| 700 | 1 | |a Perez-Ordonez, Bayardo |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Zhen |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Yangqiao |e verfasserin |4 aut | |
| 700 | 1 | |a Singaravelan, Nitthusha |e verfasserin |4 aut | |
| 700 | 1 | |a Bratman, Scott V |e verfasserin |4 aut | |
| 700 | 1 | |a Siu, Lillian L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell death and differentiation |d 1994 |g 31(2024), 4 vom: 26. Apr., Seite 460-468 |w (DE-627)NLM093807007 |x 1476-5403 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2024 |g number:4 |g day:26 |g month:04 |g pages:460-468 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41418-024-01272-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2024 |e 4 |b 26 |c 04 |h 460-468 | ||